Clinical Trials Logo

Autoimmune Hemolytic Anemia clinical trials

View clinical trials related to Autoimmune Hemolytic Anemia.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05057481 Active, not recruiting - Clinical trials for Systemic Lupus Erythematosus

Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus

Start date: September 15, 2021
Phase: Phase 3
Study type: Interventional

There is a deficiency in guidelines about the treatment of autoimmune hemolytic anemia in systemic lupus erythematosus (SLE), especially in refractory cases. Mycophenolate mofetil (MMF) showed promising results in those patients but still, the data available are in form of case reports. So, investigators will investigate the efficiency of MMF against a well-established treatment Rituximab in the treatment of refractory autoimmune hemolytic anemia in SLE patients.

NCT ID: NCT04657094 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia

Start date: March 16, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effect of acalabrutinib in treating autoimmune hemolytic anemia that has come back (relapsed) or has not responded to previous treatment (refractory) in patients with chronic lymphocytic leukemia. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03576742 Active, not recruiting - Clinical trials for Immune Thrombocytopenia

Severe Immune Cytopenia Registry Www.Sic-reg.Org

sic-reg
Start date: March 9, 2018
Phase:
Study type: Observational [Patient Registry]

Prospective registry study for children and young adults with severe immune cytopenias (persisting/chronic immune thrombocytopenia, autoimmune hemolytic anemia, and Evans syndrome) to improve the management, facilitate the differential diagnostic work-up, and document the clinical course under various treatments. Time points: at inclusion, after 6 months, after 12 months, then yearly up to 4 years after inclusion. No intervention, mere observation and documentation. Guided pre-inclusion (differential) diagnostic work-up.